Filament Health Announces Annual General Meeting Voting Results

Vancouver, British Columbia, June 28, 2022  – Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical‐stage natural psychedelic drug development company, is pleased to announce that shareholders overwhelmingly approved all proposed resolutions at its Annual General Meeting (”AGM”) of shareholders held virtually this morning.  At the AGM, there were 28 holders of the common shares […]

Filament Health Announces Patient Dosing Through Health Canada Special Access Program

Vancouver, British Columbia, June 16, 2022  – Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that a patient has been dosed with one of Filament’s drug candidates through the Health Canada Special Access Program (SAP). Filament is continuing the development of its drug candidates through clinical trials […]

Filament Health Cultivates 70th Psychedelic Mushroom Variety And Announces Annual General Meeting

Vancouver, British Columbia, June 10, 2022  – Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that it has cultivated its 70th variety of psilocybin-containing mushrooms at its 3,500 square foot GMP-compliant facility in Metro Vancouver. Filament also announced the successful development of standardized, pharmaceutical-grade ayahuasca extract, designed […]

Filament Health is Issued Second Patent by United States Patent and Trademark Office and Reports Q1 Results

The patent describes the extraction and standardization of stable doses of psychedelic compounds The Company also reports first quarter 2022 financial results and operational highlights   Vancouver, British Columbia, May 18, 2022 – Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a second […]

Filament Health Announces Pre-IND Meeting With United States Food and Drug Administration

Vancouver, British Columbia, April 12, 2022  – Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced it has held a pre-investigational new drug application (PIND) meeting with the United States Food and Drug Administration (FDA) Division of Psychiatry (The Division). During the course of the meeting, Filament and […]